Search
for
Sort by
Research 841–870 of 1000+
- Development of polycystic ovary syndrome: involvement of genetic and environmental factors
- Polycystic ovary syndrome and insulin-resistant hyperinsulinemia
- Defects in Androgen Biosynthesis Causing 46,XY Disorders of Sexual Development
- Cardiovascular risk factors and events in women with androgen excess
- Culture of the human pilosebaceous unit, hair follicle and sebaceous gland
- Is early onset androgenic alopecia a marker of metabolic syndrome and carotid artery atherosclerosis in young Indian male patients?
- Hirsutism in the Adolescent Female
- Investigating metabolic syndrome markers and body mass index changes in patients with acne vulgaris treated with isotretinoin: A prospective study
- 4 Anti-androgens in gynaecological practice
- Impaired metabolic effects of metformin in men with early-onset androgenic alopecia
- Polycystic ovary syndrome: An update on diagnosis and management
- Cross-kingdom delivery and putative gene modulation of androgen pathways by plant-derived exosome-like nanoparticles from polygoni multiflori radix promotes hair growth via miRNA cargo
- Functional Ingredient Mapping in PCOS Formulations: Hormonal Excess
- Early androgen activity after birth determines the hypothalamic expression of androgen and estrogen receptors in adulthood in female but not in male rats
- 1173 The Role of Iron Metabolism in Obstructive Sleep Apnea Severity in Individuals with Androgenetic Alopecia (EPISONO)
- Androgen excess disorders remain undiagnosed in one of every four premenopausal women with Type 1 diabetes
- Faculty Opinions recommendation of Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.
- Up-regulation of androgen receptor by heat shock protein 27 and miR-1 induces pathogenesis of androgenic alopecia.
- The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial
- Discovery of (2<i>S</i>)-<i>N</i>-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment
- From male PCOS to male endocrine-metabolic syndrome: a gender-neutral hypothesis
- Is Early-onset Androgenetic Alopecia Associated with Metabolic Syndrome? – A Descriptive Cross-sectional Study
- Early-onset Male Androgenetic Alopecia and Metabolic Syndrome: Are They Associated?
- Inhibition of skin 5α-reductase by oral contraceptive progestins<i>in vitro</i>
- Female Pattern Hair Loss
- Clinical, ultrasound and hormonal markers of androgenicity in acne vulgaris
- Pre-receptor regulation of the androgen receptor
- A Mouse Model of Androgenetic Alopecia
- ANTIANDROGEN AND HORMONAL TREATMENT OF ACNE
- Intracrine and Myotrophic Roles of 5α-Reductase and Androgens